‘Next-Gen’ Immunotherapy Active in Advanced Cancers
November 16, 2020 5:00 pmDisease control in two-thirds of patients treated with bispecific antibody.
By Charles Bankhead
An investigational drug that combines PD-1/L1 inhibition and T-cell stimulation led to disease control in two-thirds of patients with unresectable advanced solid malignancies, a preliminary clinical study … Read more